natgillin/translations-raw huggingface dataset:
Občasne: Dušenje, oteženo dihanje po naporu, hemoptiza, hipoksija, nazalna kongestija, aspiracijska pljučnica, produktivni kašelj, respiratorna depresija, kongestija dihalnih poti, piskajoče dihanje
Uncommon: Choking, dyspnoea exertional, haemoptysis, hypoxia, nasal congestion, pneumonia aspiration, productive cough, respiratory depression, respiratory tract congestion, wheezing
Občasne: Ginekomastija
Uncommon: Gynaecomastia
Občasne: Gluhota, tinitus, poslabšanje tinitusa
Uncommon: Deafness, tinnitus, tinnitus aggravated
Občasne: Levkocitoza
Uncommon: Leukocytosis
Občasne: Mrzel pot, dermatitis, neobičajna poraščenost, večje nagnjenje k podplutbam, keloidna brazgotina, nočno potenje, izpuščaj, ki nastane kot posledica izpostavljenosti svetlobi, makularni izpuščaj, luskasti izpuščaj, krastavost, boleča brazgotina, vitiligo.
Uncommon: Cold sweat, dermatitis, hair growth abnormal, increased tendency to bruise, keloid scar, night sweats, photosensitive rash, rash macular, rash scaly, scab, scar pain, vitiligo.
Občasne: Obarvano materino znamenje
Uncommon: Pigmented naevus
Občasni
Adverse Drug Reaction
Občasni
Common
Občasni
hypotension
občasni
Sexual dysfunction
občasni
Uncommon
Občasni
Very common
Občasni (lahko se pojavijo pri manj kot 1 od 100 ljudi):
Uncommon (may affect up to 1 in 100 people):
Občasni (pojavijo se lahko pri 1 od 100 bolnikov):
Uncommon (may affect up to 1 in 100 people):
občasni (pojavijo se pri 1 od 10 živali od 1.000 živali)
uncommon (more than 1 but less than 10 animals in 1,000 animals)
občasni (pri več kot 1 toda manj kot 10 živalih od 1000 živali)
uncommon (more than 1 but less than 10 animals in 1,000 animals)
Občasni neželeni učinki
Uncommon side effects
občasni neželeni učinki (≥1/1.000 do <1/100)
Very rare ARs° (<1/10,000)
Občasni:
Uncommon
Občasni:
Uncommon:
Občasni: depresija
Uncommon: Depression
Občasni: Dispneja, kašelj, bronhokonstrikcija
Dyspnoea, cough, bronchoconstriction
Občasni: Redki:
Uncommon: Rare:
Občasno (lahko prizadene 1 do 10 izmed 1.000 bolnikov)
Uncommon (may affect 1 to 10 patients in 1,000)
Občasno je vnetje podkožnega tkiva (‘celulitis’) (pojavi se lahko pri največ 1 od 100 bolnikov).
Inflammation of tissue under the skin (‘cellulitis’) is uncommon (may affect up to 1 in 100 people)
Občasno se pojavi pasavec (boleč izpuščaj v obliki mehurčkov - herpes zoster) (pojavi se lahko pri največ 1 od 100 bolnikov).
Shingles (a type of painful rash with blisters) are uncommon (may affect up to 1 in 100 people)
Občasno so v kliničnih študijah pemetrekseda, običajno ob sočasnem dajanju z drugo citotoksično učinkovino, poročali o resnih srčnožilnih dogodkih, vključno z miokardnim infarktom in možganskožilnimi dogodki.
Serious cardiovascular events, including myocardial infarction and cerebrovascular events have been uncommonly reported during clinical studies with pemetrexed, usually when given in combination with another cytotoxic agent.
Občasno:
Uncommon:
občutek omotičnosti
Feeling dizzy
Občutek splošne oslabelosti in utrujenosti, ki sta lahko znaka zmanjšanega števila rdečih krvničk (anemija).
Feeling generally weak and tired, which can be symptoms of a decrease in the number of red blood cells (anaemia).
občutek utrujenosti
Feeling tired
občutek utrujenosti ali težkega dihanja, kašelj, ki ne mine
feeling tired or short of breath; cough which will not go away
Občutljivost na svetlobo
Photosensitivity
Občutljivost oči
Ocular sensitivity
ocBo6o)K)],aBaHe
(multipack)
Oceanside, CA 92056 5802
Oceanside, CA 92056 5802 USA
Ocenjeni učinki zdravljenja na MGK so bili podobni pri obeh učinkovinah, vendar načrt preskušanja ni bil dovolj robusten, da bi lahko potrdili neinferiornost zoledronske kisline.
Estimated treatment effects on BMD were similar, but the trial design was not sufficiently robust to establish non-inferior efficacy for zoledronic acid.
Ocenjeno je, da se z blatom izloči 18 % skupnega topotekana in 1,7 % N-desmetil topotekana.
Faecal elimination of total topotecan accounted for 18 % while faecal elimination of N-desmethyl topotecan was
och systemiska
Eosinophilia and
Oclacitinib модулира имунната система и може да увеличи възприемчивостта към инфекциозни заболявания и да влоши неоплазии.
Oclacitinib modulates the immune system and may increase susceptibility to infection and exacerbate neoplastic conditions.
Oclacitinib се свързва с нискомолекулни протеини в 66.3% до 69.7%, свързани с кучешка плазма при номинални концентрации, които варират от 10 до 1000 ng/ml.
Oclacitinib exhibits low protein binding with 66.3% to 69.7% bound in fortified canine plasma at nominal concentrations ranging from 10 to 1,000 ng/ml.
OCT2 е транспортерът, отговорен за активната секреция на фампридин.
OCT2 is the transporter responsible for the active secretion of fampridine.
Octapharma AB, Lars Forssells gata 23, 112 75 Stockholm, Швеция
Octapharma AB, Lars Forssells gata 23, 112 75 Stockholm, Sweden
Od 97 bolnikov, ki so jih zdravili z zdravilom INOmax, so 2 (2 %) izključili iz študije zaradi koncentracij methemoglobina >4 %.
Of the 97 patients treated with INOmax, 2(2 %) were withdrawn from study drug due to methaemoglobin levels >4 %.
Od kovinskih materialov se priporoča samo nerjaveče jeklo.
Among metallic construction materials, only stainless steel can be recommended.
Od snovi, ki udušijo aktivne vrste kisika, ali sproščajo radikale, kot so dimetilsulfoksid, b-karoten, etanol, format in manitol, bi pričakovali, da zmanjšajo delovanje PDT.
Compounds that quench active oxygen species or scavenge radicals, such as dimethyl sulphoxide, b- carotene, ethanol, formate and mannitol would be expected to decrease PDT activity.
Od teh jih je približno 1.000 v bolj napredovalih stadijih sočasno prejemalo levodopo in so trpeli za motoričnimi zapleti.
Out of these, approximately 1,000 were in more advanced stages, received concomitant levodopa therapy, and suffered from motor complications.
Od zdravotníckych pracovníkov sa vyžaduje, aby hlásili akékoľvek podozrenia na nežiaduce reakcie na národné centrum hlásenia uvedené v Prílohe V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Od zdravstvenih delavcev se zahteva, da poročajo o katerem koli domnevnem neželenem učinku zdravila na nacionalni center za poročanje, ki je naveden v Prilogi V.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V
Odbor CHMP se strinja z znanstvenimi zaključki odbora PRAC.
The CHMP agrees with the scientific conclusions made by the PRAC.
Odbor CHMP zato priporoča spremembo pogojev dovoljenja (dovoljenj) za promet z zdravilom.
The CHMP recommends that the terms of the marketing authorisation(s) should be varied.
Odds Ratio 2,77
Odds Ratio 2.77
Odds Ratio 3,02
Odds Ratio 3.02
Odds Ratio 3,45
Odds Ratio 3.45
Odefsey 200 mg/25 mg/25 mg филмирани таблетки
Odefsey 200 mg/25 mg/25 mg film-coated tablets
Odefsey 200 mg/25 mg/25 mg филмирани таблетки емтрицитабин/рилпивирин/тенофовир алафенамид
Odefsey 200 mg/25 mg/25 mg film-coated tablets emtricitabine/rilpivirine/tenofovir alafenamide
Odefsey [Само на външната опаковка]
Odefsey [Outer packaging only]
Odefsey fih is-sustanzi attivi emtricitabine, rilpivirine u tenofovir alafenamide.
What is Odefsey and what is it used for?
Odefsey fih tliet sustanzi attivi.
Odefsey contains three active substances.
Odefsey не трябва да се прилага съвместно с други антиретровирусни лекарствени продукти, които съдържат тенофовир алафенамид, ламивудин, тенофовир дизопроксил (като фумарат) или адефовир дипивоксил (вижте точка 4.5).
Odefsey should not be co-administered with other medicinal products containing tenofovir alafenamide, lamivudine, tenofovir disoproxil (as fumarate) or adefovir dipivoxil (see section 4.5).
Odefsey трябва да се използва по време на бременност само ако потенциалната полза оправдава потенциалния риск за плода.
Odefsey should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Odefsey трябва да се използва с повишено внимание при едновременно приложение с лекарствен продукт с известен риск за Torsade de Pointes (вижте точка 4.4).
Odefsey should be used with caution when co-administered with a medicinal product with a known risk of Torsade de Pointes (see section 4.4).
Odefsey трябва да се използва с повишено внимание при едновременно приложение с лекарствени продукти с известен риск за Torsade de Pointes.
Odefsey should be used with caution when co-administered with medicinal products with a known risk of Torsade de Pointes.
Odefsey трябва да се прекрати при пациенти с изчислен креатининов клирънс, който спада под 30 ml/min по време на лечение (вж. точки 5.1 и 5.2).
Odefsey should be discontinued in patients with estimated creatinine clearance that declines below 30 mL/min during treatment (see sections 5.1 and 5.2).
Odefsey: Нивата на експозиция на емтрицитабин и на тенофовир алафенамид са биоеквивалентни при сравняване на една филмирана таблетки Odefsey 200/25/25 mg с комбинирана таблетка с фиксирана доза (150/150/200/10 mg) елвитегравир/кобицистат/емтрицитабин/тенофовир алафенамид след еднократно приложение при здрави пациенти (n = 82) след прием на храна.
Odefsey: Emtricitabine and tenofovir alafenamide exposures were bioequivalent when comparing one Odefsey 200/25/25 mg film-coated tablet to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (150/150/200/10 mg) fixed-dose combination tablet following single dose administration to healthy subjects (n = 82) under fed conditions.
ODIN е Фаза III, рандомизирано, открито проучване, сравняващо PREZISTA/ритонавир 800/100 mg веднъж дневно с PREZISTA/ритонавир 600/100 mg два пъти дневно при HIV-1 инфектирани пациенти, преминали ART, чиито резултати от скрининг теста за генотипна резистентност не сочат мутации, свързани с резистентност към дарунавир (т.е.
ODIN is a Phase III, randomised, open-label trial comparing PREZISTA/ritonavir 800/100 mg once daily versus PREZISTA/ritonavir 600/100 mg twice daily in ART-experienced HIV-1 infected patients with screening genotype resistance testing showing no darunavir RAMs (i.e.
Odmerek
Injection volume
Odmerek (mg soli)
Dose (mg of salt)
Odmerek (mg)
Dose (mg of base)
Odmerek (mg)
Dose (mg)
Odmerek boste po zdravnikovih navodilih vsakih 5 do 7 dni povečevali, dokler ne bodo simptomi minili (vzdrževalni odmerek).
This will be increased every 5-7 days as directed by your doctor until your symptoms are controlled (maintenance dose).
Odmerek cisplatina (mg/m2)
Dose for cisplatin (mg/m2)
Odmerek in potrebno število vial zdravila STELARA izračunajte na osnovi bolnikove telesne mase (glejte poglavje 4.1, preglednica 1).
Calculate the dose and the number of STELARA vials needed based on patient weight (see section 3, Table 1).
Odmerek in potrebno število vial zdravila STELARA izračunajte na osnovi bolnikove telesne mase (glejte poglavje 4.2, preglednica 1).
Calculate the dose and the number of STELARA vials needed based on patient weight (see section 4.2, Table 1).
Odmerek je treba dati v enkratni intravenski infuziji v času, ki ne sme biti krajši od 15 minut.
The dose must be given as a single intravenous infusion over no less than 15 minutes.
Odmerek je treba prilagoditi, kot je priporočeno v poglavju 4.2.
The dose should be modified as recommended in section 4.2.
Odmerek pri otrocih, ki tehtajo manj kot 60 kg, je manjši od 45 mg.
Children weighing less than 60 kg need a dose lower than 45 mg.
Odmerek se lahko poveča do 20 ppm, če uporabljeni odmerek nima zadostnih kliničnih učinkov.
The dose may be increased up to 20 ppm if the lower dose has not provided sufficient clinical effects.
Odmerek se lahko poveča do 40 ppm, če uporabljeni odmerek nima zadostnih kliničnih učinkov.
The dose may be increased up to 40 ppm if the lower dose has not provided sufficient clinical effects.
Odmerek v mg
mg. administered
Odmerek zdravila Pemetreksed Hospira (mg/m2)
Dose of Pemetrexed Hospira (mg/m2)
Odmerek zdravila Pemetreksed Hospira je 500 miligramov za vsak kvadratni meter površine vašega telesa.
The dose of Pemetrexed Hospira is 500 milligrams for every square metre of your body’s surface area.
Odmerek zdravila Teysuno
Teysuno dose
Odmerek zdravila Teysuno se spremeni znotraj 21-dnevnega cikla zdravljenja
Teysuno dose changes within a 21-day treatment cycle
Odmerek zdravila Teysuno zaradi toksičnosti se lahko, če se to zdravilo uporablja v kombinaciji s cisplatinom, spreminja na dva načina.
Teysuno dose modifications for toxicity when used in combination with cisplatin can be made in two ways.
Odmerek zdravila Topotekan Teva bo morda treba prilagoditi.
Your dose of Topotecan Teva may need to be adjusted.
Odmerjanja pri starejših ni potrebno prilagoditi.
No dose adjustment is necessary for the elderly.
Odmerjanje
Dosage
Odmerjanje
Posology
Odmerjanje in način uporabe
Posology and method of administration
Odmerjanje in način uporabe Odmerjanje
Posology and method of administration
Odmerjanje in pot uporabe
Amounts to be administered and administration route
Odmerjanje in pot uporabe
Posology and method of administration
Odmerjanje in pot uporabe
Route and method of administration
Odmerjanje:
Posology:
Odmerka glede na spol bolnika ni potrebno prilagajati.
No dosage adjustment is necessary based on gender.
Odmerka ni treba prilagoditi starosti bolnika.
Dose modification based upon age is not required.
Odmerka, ki ste ga izbruhali, ne nadomeščajte.
Do not replace the dose that has been vomited.
Odmerki pramipeksola, kot jih navajajo v literaturi, se nanašajo na sol.
Pramipexole doses as published in the literature refer to the salt form.
Odmerki pramipeksola, večji od 1,1 mg baze (1,5 mg soli) na dan, so lahko koristni pri bolnikih z napredovalo Parkinsonovo boleznijo, pri katerih je predvideno zmanjšanje zdravljenja z levodopo.
In advanced Parkinson’s disease, pramipexole doses higher than 1.1 mg of base (1.5 mg of salt) per day can be useful in patients where a reduction of the levodopa therapy is intended.
Odmerki svetlobe
Light doses
ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT(I) IN NAČIN UPORABE ZDRAVILA
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
Odmerki zdravila Teysuno
Teysuno doses
Odmerki, ki so bili izpuščeni zaradi toksičnosti, se ne nadomestijo; prav tako se odmerek ne nadomesti, če bolnik po prejemu odmerka bruha.
Doses omitted for toxicity are not replaced; and, if a patient vomits after taking a dose, this dose should not be replaced.
Odomzo 200 mg капсули Сонидегиб
Odomzo 200 mg capsules Sonidegib
Odomzo 200 mg капсули са розови и непрозрачни.
Odomzo 200 mg capsules are pink and opaque.
Odomzo 200 mg твърди капсули
Odomzo 200 mg hard capsules
Odomzo 200 mg твърди капсули Сонидегиб
Odomzo 200 mg hard capsules Sonidegib
Odomzo е противопоказан при жени с детероден потенциал, които не се придържат към Програмата за превенция на бременност при лечение с Odomzo.
Odomzo is contraindicated in women of childbearing potential who do not comply with the Odomzo Pregnancy Prevention Programme.
Odomzo може да повлияе фертилитета при мъже и жени.
Odomzo may have an impact on fertility in men and women.
Odomzo може да предизвика мускулни проблеми.
Odomzo may cause muscle problems.
Odomzo не трябва да се приема от жени, които потенциално могат да забременеят, освен ако те спазват Програмата за превенция на бременност при лечение с Odomzo.
Women who could potentially become pregnant must not take Odomzo unless they comply with the Odomzo pregnancy prevention programme.
Odomzo съдържа активното вещество сонидегиб.
Odomzo contains the active substance sonidegib.
Odpadne snovi odstranite s prekuhavanjem, sežigom ali potopitvijo v ustreznem dezinfekcijskem sredstvu, katerega uporabo odobrijo pristojni organi.
Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.
Odpadni material odvrzite v skladu z lokalnimi predpisi.
Dispose of waste material in accordance with local requirements.
Odpadno tekočino lahko sperete z veliko količino vode
Liquid waste may be flushed with large amounts of water.
Odpadno tekočino lahko sperete z veliko količino vode.
Liquid waste may be flushed with large amounts of water.
Odporúča sa sledovať u pacientov príznaky alebo symptómy srdcovej dysfunkcie.
It is recommended to monitor patients for clinical cardiac signs or symptoms.
Odporúčaná dávka na liečbu karcinómu vaječníkov je 1,1 mg/m2 povrchovej plochy tela po podaní 30 mg/m2 povrchovej plochy tela PLD.
For the treatment of ovarian cancer, the usual dose is 1.1 mg/m2 body surface area after the administration of 30 mg/m2 body surface area of PLD.
Odporúčaná dávka na liečbu sarkómu mäkkého tkaniva je 1,5 mg/m2 povrchovej plochy tela.
For the treatment of soft tissue sarcoma, the usual dose is 1.5 mg/m2 of body surface area.
odpoved več organov, znižan indeks zmogljivosti, bolečina, edemi, bolečine v prsnem košu, stiskanje v prsnem košu, generaliziran edem, edem obraza, lokalno otekanje, lokaliziran edem, povečanje telesne mase, zgodnja sitost, občutek mraza, reakcija na mestu injiciranja, slabo počutje
Multi-organ failure, performance status decreased, pain, oedema, chest pain, chest discomfort, generalized oedema, face oedema, local swelling, localized oedema, weight increased, early satiety, feeling cold, injection site reaction, malaise
Odprto zdravilo uporabite v 8 tednih.
Once opened use within 8 weeks
Odrasli bolniki z rakomb
Adults Cancer Patientsb
Odrasli in starostniki
Adults and older people
Odrasli, stari 18 let in več
Adults aged 18 years or older
Odrasli, stari 18 let in več Psoriaza ali psoriatični artritis
Adults aged 18 years or older Psoriasis or Psoriatic Arthritis
Odrasli:
Adults:
odrevenelost, občutek pečenja, zbadanja ali mravljinčenja na koži
numbness, burning, prickling or tingling sensations on the skin
Odstotek bolnikov, ki so prejeli zdravljenje po študiji, je bil 64,3 % za pemetreksed in 71,7 % za placebo.
The percentage of patients that received post-study treatment was 64.3% for pemetrexed and 71.7% for placebo.
Odstotek bolnikov, pri katerih se je razvil rak, je bil v skupini, zdravljeni s PhotoBarrom PDT + OM, statistično pomembno nižji kot v skupini, zdravljeni zgolj z OM (p=0,0060).
The proportion of patients who progressed to cancer in the PhotoBarr PDT + OM group was statistically lower than in the OM only group (p=0.0060).
Odstotek odziva na topotekan pri kombiniranem režimu zdravljenja drobnoceličnega pljučnega raka (n = 480) pri bolnikih z relapsom bolezni, dovzetne na zdravljenje s terapijo prve izbire, je bil 20,2 %.
The response rate to topotecan in the combined small cell lung cancer programme (n=480) for patients with relapsed disease sensitive to first-line therapy, was 20.2 %.
Odstranite pokrovček z igle (glejte Sliko 3)
Remove the needle cover (see Figure 3):
Odstranjevanje
Disposal
Odstranjevanje
Disposal:
Odsvetovana sočasna uporaba: Živa oslabljena cepiva (razen proti rumeni mrzlici, za katero je sočasna uporaba kontraindicirana): tveganje za sistemsko, potencialno smrtno bolezen.
Concomitant use not recommended: Live attenuated vaccines (except yellow fever, for which concomitant use is contraindicated): risk of systemic, possibly fatal, disease.
Odziv (N: ustrezen odziv)
(N = 264)
odziv ACR 20 N (%)
ACR 20 response, N (%)
odziv ACR 50 N (%)
ACR 50 response, N (%)
odziv ACR 70 N (%)
ACR 70 response, N (%)
Odziv PASI 100
PASI 100 responders
odziv PASI 50 N (%)
PASI 50 response N (%)
Odziv PASI 75
PASI 75 responders
odziv PASI 75 N (%)
PASI 75 response N (%)
odziv PASI 75 N (%)
PASI 75 response, N (%)
odziv PASI 75 r N (%)
PASI 75 response, N (%)
Odziv PASI 90
PASI 90 responders
odziv PASI 90 N (%)
PASI 90 response N (%)
odziv PASI 90 N (%)
PASI 90 response, N (%)
Odzivi v skupininah bolnikov, ki so prejemale ustekinumab so bili podobni odzivu pri bolnikih, ki so/niso prejemali MTX sočasno in so se ohranili do 52. in do 100. tedna.
Responses observed in the ustekinumab treated groups were similar in patients receiving and not receiving concomitant MTX, and were maintained through weeks 52 and 100.
Oesophagostomum spp (възрастни форми)
Oesophagostomum spp. (adult stages)
Ofev 100 mg капсули нинтеданиб
Ofev 100 mg capsules nintedanib
Ofev 100 mg меки капсули Ofev 150 mg меки капсули
Ofev 100 mg soft capsules Ofev 150 mg soft capsules
Ofev 100 mg меки капсули нинтеданиб
Ofev 100 mg soft capsules nintedanib
Ofev 100 mg меки капсули са непрозрачни, продълговати меки желатинови капсули с цвят на праскова, с отпечатани в черно от едната страна лого фирма Boehringer Ingelheim и „100“.
Ofev 100 mg capsules are peach-coloured, opaque, oblong soft-gelatin capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and the figure “100”.
Ofev 100 mg меки капсули са непрозрачни, продълговати, меки желатинови капсули с цвят на праскова, с отпечатани в черно от едната страна лого Boehringer Ingelheim и „100“.
Ofev 100 mg soft capsules are peach-coloured, opaque, oblong soft-gelatin capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and “100”.
Ofev 100 mg меки капсули/Ofev 150 mg меки капсули се предлагат в следните опаковки:
Ofev 100 mg soft capsules/ Ofev 150 mg soft capsules are available in the following pack-sizes:
Ofev 150 mg два пъти дневно
Ofev 150 mg twice daily
Ofev 150 mg капсули нинтеданиб
Ofev 150 mg capsules nintedanib
Ofev 150 mg меки капсули нинтеданиб
Ofev 150 mg soft capsules nintedanib
Ofev 150 mg меки капсули са непрозрачни продълговати меки желатинови капсули с кафяв цвят, с отпечатани в черно от едната страна лого Boehringer Ingelheim и числото „150“.
Ofev 150 mg capsules are brown-coloured, opaque, oblong soft-gelatin capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and the figure “150”.
Ofev 150 mg меки капсули са непрозрачни, продълговати меки желатинови капсули с цвят на праскова, с отпечатани в черно от едната страна лого Boehringer Ingelheim и „150“.
Ofev 150 mg soft capsules are brown-coloured, opaque, oblong soft-gelatin capsules imprinted on one side in black with the Boehringer Ingelheim company symbol and “150”.
Ofev е показан при възрастни за лечение на идиопатична белодробна фиброза (ИБФ).
Ofev is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Ofev не трябва да се приема от деца и юноши на възраст под 18 години.
Ofev should not be taken by children and adolescents under 18 years of age.
Ofev съдържа активното вещество нинтеданиб (nintedanib).
Ofev contains the active substance nintedanib.
Ofev съдържа активното вещество нинтеданиб и се използва за лечение на идиопатична белодробна фиброза (ИБФ).
Ofev contains the active substance nintedanib and it is used for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Ofev съдържа активното вещество нинтеданиб и се използва за лечение на идиопатична белодробна фиброза (ИБФ)..
Ofev contains the active substance nintedanib and it is used for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Ofev съдържа соев лецитин
Ofev contains soya lecithin
OFF период (ч) (в)
OFF time (hrs) (c)
Oftalmološki pregledi
Ophthalmologic monitoring
Oförändrad avibaktam var den huvudsakliga läkemedelskomponenten i human plasma och urin efter dosering med [14C]-avibaktam.
Unchanged avibactam was the major drug-related component in human plasma and urine following dosing with [14C]-avibactam.
Ohutusandmete analüüsimisel soo või rassi järgi kliiniliselt olulisi erinevusi ei täheldatud.
No clinically significant differences were seen when the safety data were analysed by gender or race.
Ohutusprofiili kokkuvõte
Summary of the safety profile
Okrajšava: IZ = interval zaupanja
Abbreviation: CI = confidence interval.
Okrajšave: ALT = alaninska aminotransferaza; AST = aspartatna aminotransferaza; CTCAE = običajni terminološki kriteriji za neželene učinke; NCI = nacionalni inštitut za rakava obolenja; SGOT = serumska glutamat oksalocetna aminotransferaza; SGPT = serumska glutamat piruvična aminotransferaza.
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute; SGOT = serum glutamic oxaloacetic aminotransferase; SGPT = serum glutamic pyruvic aminotransferase.
okužba pljuč
lung infection